Reference
Pivniouk, Vadim, et al. “Airway Administration of {OM-85}, a Bacterial Lysate, Blocks Experimental Asthma by Targeting Dendritic Cells and the {epithelium IL-33 ILC2} Axis”. J. Allergy Clin. Immunol., vol. 149, no. 3, Mar. 2022, pp. 943–956.
Abstract
BACKGROUND: Microbial interventions against allergic asthma have
robust epidemiologic underpinnings and the potential to
recalibrate disease-inducing immune responses. Oral
administration of OM-85, a standardized lysate of human airways
bacteria, is widely used empirically to prevent respiratory
infections and a clinical trial is testing its ability to
prevent asthma in high-risk children. We previously showed that
intranasal administration of microbial products from farm
environments abrogates experimental allergic asthma. OBJECTIVES:
We sought to investigate whether direct administration of OM-85
to the airway compartment protects against experimental allergic
asthma; and to identify protective cellular and molecular
mechanisms activated through this natural route. METHODS:
Different strains of mice sensitized and challenged with
ovalbumin or Alternaria received OM-85 intranasally, and
cardinal cellular and molecular asthma phenotypes were measured.
Airway transfer experiments assessed whether OM-85-treated
dendritic cells protect allergen-sensitized, OM-85-naive mice
against asthma. RESULTS: Airway OM-85 administration suppressed
allergic asthma in all models acting on multiple innate and
adaptive immune targets: the airway epithelium/IL-33/ILC2 axis,
lung allergen-induced type 2 responses, and dendritic cells
whose Myd88/Trif-dependent tolerogenic reprogramming was
sufficient to transfer OM-85-induced asthma protection.
CONCLUSIONS: We provide the first demonstration that
administering a standardized bacterial lysate to the airway
compartment protects from experimental allergic asthma by
engaging multiple immune pathways. Because protection required a
cumulative dose 27- to 46-fold lower than the one reportedly
active through the oral route, the efficacy of intranasal OM-85
administration may reflect its direct access to the airway
mucosal networks controlling the initiation and development of
allergic asthma.